Metabolisme in 'winterslaap' bij myalgische encefalomyelitis/chronische-vermoeidheidssyndroom
Een nieuw therapeutisch doelwit?

Myalgische encefalomyelitis/chronische-vermoeidheidssyndroom (ME/CVS), tegenwoordig ook wel systemic exercise intolerance disease (SEID), is een heterogene ziekte met een onbekende oorzaak. Het betreft een ernstige chronische ziekte, die het functioneren en de kwaliteit van leven aanzienlijk beperkt. De belangrijkste symptomen zijn vermoeidheid gedurende meer dan zes maanden, malaise na inspanning, slaapstoornissen, onvoldoende herstel na rust en slaap, cognitieve stoornissen, geheugen- en concentratieproblemen, spier- en gewrichtspijn, sensorische hypergevoeligheid en autonome disfunctie, waaronder orthostatische intolerantie. Er is geen overeenstemming of ME en CVS twee verschillende ziektes zijn en er is geen consensus over de diagnose en therapie. Diagnostiek conform de vijf criteria van het Amerikaanse Institute of Medicine (IOM) heeft momenteel de voorkeur.1 Cognitieve gedragstherapie (CBT) en graded exercise therapy (GET) behoren tot de therapeutische mogelijkheden,1 maar het succes daarvan is omstreden.2

Beste bezoeker, u heeft geen toegang.

Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.

U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!

Auteur

Frits Muskiet

Trefwoorden:

Figuren

Verschenen in

Referenties

  1. Gezondheidsraad. ME/CVS. Den Haag: 19 maart 2018. [https://www.gezondheidsraad.nl/sites/default/files/grpublication/kernadvies_me_cvs_1.pdf no. Gezondheidsraad Nr. 2018/07.]

  2. Wilshire CE, Kindlon T, Courtney R, Matthees A, Tuller D, Geraghty K, Levin B. Rethinking the treatment of chronic fatigue syndrome-a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT. BMC Psychol 2018;6:6,018-0218-3.

  3. Brooks SK, Chalder T, Rimes KA. Chronic Fatigue Syndrome: Cognitive, Behavioural and Emotional Processing Vulnerability Factors. Behav Cogn Psychother 2017;45:156-69.

  4. Ruiz-Nunez B, Tarasse R, Vogelaar EF, Janneke Dijck-Brouwer DA, Muskiet FAJ. Higher Prevalence of "Low T3 Syndrome" in Patients With Chronic Fatigue Syndrome: A Case-Control Study. Front Endocrinol (Lausanne) 2018;9:97.

  5. Montoya JG, Holmes TH, Anderson JN, Maecker HT, Rosenberg-Hasson Y, Valencia IJ, Chu L, Younger JW, Tato CM, Davis MM. Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc Natl Acad Sci U S A 2017;114:E7150-8.

  6. Morris G, Berk M, Walder K, Maes M. The Putative Role of Viruses, Bacteria, and Chronic Fungal Biotoxin Exposure in the Genesis of Intractable Fatigue Accompanied by Cognitive and Physical Disability. Mol Neurobiol 2016;53:2550-71.

  7. Embers ME, Hasenkampf NR, Jacobs MB, Tardo AC, Doyle-Meyers LA, Philipp MT, Hodzic E. Variable manifestations, diverse seroreactivity and post-treatment persistence in non-human primates exposed to Borrelia burgdorferi by tick feeding. PLoS One 2017;12:e0189071.

  8. Navaneetharaja N, Griffiths V, Wileman T, Carding SR. A Role for the Intestinal Microbiota and Virome in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)? J Clin Med 2016;5:10.3390/jcm5060055.

  9. Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome 2016;4:30,016-0171-4.

  10. Newberry F, Hsieh SY, Wileman T, Carding SR. Does the microbiome and virome contribute to myalgic encephalomyelitis/chronic fatigue syndrome? Clin Sci (Lond) 2018;132:523-42.

  11. Hotamisligil G. Inflammation and metabolic disorders. Nature 2006;444:860-7.

  12. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nature reviews.Immunology 2008;8:923-34.

  13. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature 2017;542:177-85.

  14. de Vega WC, Vernon SD, McGowan PO. DNA methylation modifications associated with chronic fatigue syndrome. PLoS One 2014;9:e104757.

  15. de Vega WC, Herrera S, Vernon SD, McGowan PO. Epigenetic modifications and glucocorticoid sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). BMC Med Genomics 2017;10:11,017-0248-3.

  16. de Vega WC, Erdman L, Vernon SD, Goldenberg A, McGowan PO. Integration of DNA methylation & health scores identifies subtypes in myalgic encephalomyelitis/chronic fatigue syndrome. Epigenomics 2018;10:539-57.

  17. Naviaux RK, Naviaux JC, Li K, Bright AT, Alaynick WA, Wang L, Baxter A, Nathan N, Anderson W, Gordon E. Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci U S A 2016;113:E5472-80.

  18. Naviaux RK. Metabolic features of the cell danger response. Mitochondrion 2014;16:7-17.

  19. Geanacopoulos M. The determinants of lifespan in the nematode Caenorhabditis elegans: a short primer. Sci Prog 2004;87:227-47.

  20. Fluge O, Mella O, Bruland O, Risa K, Dyrstad SE, Alme K, Rekeland IG, Sapkota D, Rosland GV, Fossa A, et al. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight 2016;1:e89376.

  21. Tomas C, Brown A, Strassheim V, Elson JL, Newton J, Manning P. Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. PLoS One 2017;12:e0186802.

  22. Patel KP, O'Brien TW, Subramony SH, Shuster J, Stacpoole PW. The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. Mol Genet Metab 2012;105:34-43.

  23. Bhandary S, Aguan K. Pyruvate dehydrogenase complex deficiency and its relationship with epilepsy frequency--An overview. Epilepsy Res 2015;116:40-52.

  24. Craig C. Mitoprotective dietary approaches for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Caloric restriction, fasting, and ketogenic diets. Med Hypotheses 2015;85:690-3.

  25. Stacpoole PW, Kurtz TL, Han Z, Langaee T. Role of dichloroacetate in the treatment of genetic mitochondrial diseases. Adv Drug Deliv Rev 2008;60:1478-87.

  26. Comhaire F. Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate: An open-label, proof-of-principle pilot trial. Med Hypotheses 2018;114:45-8.

  27. Heap LC, Peters TJ, Wessely S. Vitamin B status in patients with chronic fatigue syndrome. J R Soc Med 1999;92:183-5.

  28. Costantini A, Nappo A, Pala MI, Zappone A. High dose thiamine improves fatigue in multiple sclerosis. BMJ Case Rep 2013;2013:10.1136/bcr,2013-009144.

  29. Munujos P, Coll-Canti J, Beleta J, Gonzalez-Sastre F, Gella FJ. Brain pyruvate oxidation in experimental thiamin-deficiency encephalopathy. Clin Chim Acta 1996;255:13-25.

  30. Martin PR, Singleton CK, Hiller-Sturmhofel S. The role of thiamine deficiency in alcoholic brain disease. Alcohol Res Health 2003;27:134-42.

  31. Woolley J, Allen R, Wessely S. Alcohol use in chronic fatigue syndrome. J Psychosom Res 2004;56:203-6.

  32. Muskiet FAJ. Vitamine B6. Een oninteressante vitamine of toch niet? . Voedingsgeneeskunde 2016;17(6):44-5.

  33. Goraca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E, Skibska B. Lipoic acid - biological activity and therapeutic potential. Pharmacol Rep 2011;63:849-58.

  34. Dorsam B, Fahrer J. The disulfide compound alpha-lipoic acid and its derivatives: A novel class of anticancer agents targeting mitochondria. Cancer Lett 2016;371:12-9.

  35. Ambrosi N, Guerrieri D, Caro F, Sanchez F, Haeublein G, Casadei D, Incardona C, Chuluyan E. Alpha Lipoic Acid: A Therapeutic Strategy that Tend to Limit the Action of Free Radicals in Transplantation. Int J Mol Sci 2018;19:10.3390/ijms19010102.

  36. Campagnolo N, Johnston S, Collatz A, Staines D, Marshall-Gradisnik S. Dietary and nutrition interventions for the therapeutic treatment of chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review. J Hum Nutr Diet 2017;30:247-59.

  37. Nasser M, Javaheri H, Fedorowicz Z, Noorani Z. Carnitine supplementation for inborn errors of metabolism. Cochrane Database Syst Rev 2012;(2):CD006659. doi:CD006659.

  38. Fielding R, Riede L, Lugo JP, Bellamine A. l-Carnitine Supplementation in Recovery after Exercise. Nutrients 2018;10:10.3390/nu10030349.

  39. Ryan ZC, Craig TA, Folmes CD, Wang X, Lanza IR, Schaible NS, Salisbury JL, Nair KS, Terzic A, Sieck GC, et al. 1alpha,25-Dihydroxyvitamin D3 Regulates Mitochondrial Oxygen Consumption and Dynamics in Human Skeletal Muscle Cells. J Biol Chem 2016;291:1514-28.

Gerelateerde artikelen

Darm en autisme
Verarmd darmmicrobioom bij autisme: het leefsysteem onder stress
Zuigeling met verhoogde kans op autisme heeft onderscheidend darmmicrobioom
Voeding beïnvloedt kolonisatie van lactobacillen in de darmen
Bergafwaarts wandelen vermindert lagegraadontsteking
Luchtverontreiniging nadelig voor darmmicrobiota zuigelingen?